Latest Life Sciences News

Atomo Diagnostics has appointed Dr Cheri Walker as interim CEO, replacing founder John Kelly who steps down after 15 years. The leadership change aligns with the company's shift towards commercial growth in the US and Europe.

HealthCo Healthcare & Wellness REIT delivered strong FY26 results with 100% rent collection and solid portfolio metrics, while progressing alternative lease arrangements for its Healthscope hospital portfolio.

Vita Life Sciences delivered a robust first half in 2026 with revenue up 6.1% to A$48.3 million and net profit after tax rising 14.9% to A$5.54 million. The company declared a higher interim dividend, reflecting improved margins and regional market momentum.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Synertec has locked in a $4 million contract to upgrade AGL’s national SCADA system, reinforcing its foothold in critical infrastructure technology as it forecasts up to 50% revenue growth in FY27.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.

Amplia Therapeutics reported encouraging mature data from its ACCENT trial, initiated a Phase 2b pancreatic cancer study, launched an ovarian cancer trial, and refreshed its board leadership while maintaining a solid cash balance of A$24 million.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Microba Life Sciences has wrapped up a $5.41 million capital raise combining a $5 million institutional Placement and a $407,500 Share Purchase Plan, strengthening its balance sheet to accelerate growth in Australia and the UK.

ALS Limited reported record FY26 financial results driven by strong growth in Minerals and Industrial Materials, while advancing its digital transformation through the Lab of the Future initiative. Leadership changes and a strategic portfolio review underpin its disciplined capital allocation approach.

Vitrafy Life Sciences has partnered with the historic Hoxworth Blood Center to deploy its next-generation cryopreservation technology, aiming to address a critical gap in red blood cell preservation ahead of legacy technology discontinuation in 2027.